High intensity lipid lowering

PreclinicalSmall molecule

AAarhus University Hospital

High intensity lipid lowering is one of 7 small molecule programs targeting Lip. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LipCompleted

LipPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Lip

#DrugCompanyPhaseTrials

Monodox

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Berberine

XXijing Hospital of Digestive Diseases

Phase 3

1 3

Octreotide

Johnson & Johnson

Phase 1

1 4

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 1

1 5

Isopto Carpine

AAdvanz Pharma

Preclinical

1 6

Vyxeos

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Preclinical

1 7

High intensity lipid lowering

AAarhus University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lip1 trial

Influence of Lipid Lowering on Impaired Coronary Flow

Completed·—·N/A·NCT05368545·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for High intensity lipid lowering. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High intensity lipid lowering compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High intensity lipid lowering. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aarhus University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAarhus University Hospital

High intensity lipid lowering

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lip1 trial

References

Drug Info

Quick Facts

Related News